Literature DB >> 4008592

How should we measure function in patients with chronic heart and lung disease?

G H Guyatt, P J Thompson, L B Berman, M J Sullivan, M Townsend, N L Jones, S O Pugsley.   

Abstract

To elucidate the characteristics of measures of function in patients with chronic heart failure and chronic lung disease we administered four functional status questionnaires, a 6-min walk test and a cycle ergometer exercise test, to 43 patients limited in their day to day activities as a result of their underlying heart or lung disease. Correlations between these measures were calculated using Spearman's rank order correlation coefficient. The walk test correlated well with the cycle ergometer (r = 0.579), and almost as well with the four functional status questionnaires (r = 0.473-0.590) as the questionnaires did with one another (0.423-0.729). On the other hand, correlations between cycle ergometer results and the questionnaires was in each case 0.295 or lower, and none of these correlations reached statistical significance. These results suggest that exercise capacity in the laboratory can be differentiated from functional exercise capacity (the ability to undertake physically demanding activities of daily living) and that the walk test provides a good measure of function in patients with heart and lung disease.

Entities:  

Mesh:

Year:  1985        PMID: 4008592     DOI: 10.1016/0021-9681(85)90035-9

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  78 in total

1.  Clinically meaningful change estimates for the six-minute walk test and daily activity in individuals with chronic heart failure.

Authors:  Michael J Shoemaker; Amy B Curtis; Eric Vangsnes; Michael G Dickinson
Journal:  Cardiopulm Phys Ther J       Date:  2013-09

2.  Peak oxygen uptake. Myth and truth about an internationally accepted reference value.

Authors:  T Meyer; J Scharhag; W Kindermann
Journal:  Z Kardiol       Date:  2005-04

3.  Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease.

Authors:  C A Ketelaars; M A Schlösser; R Mostert; H Huyer Abu-Saad; R J Halfens; E F Wouters
Journal:  Thorax       Date:  1996-01       Impact factor: 9.139

4.  Activity monitoring and energy expenditure in COPD patients: a validation study.

Authors:  Sanjay A Patel; Roberto P Benzo; William A Slivka; Frank C Sciurba
Journal:  COPD       Date:  2007-06       Impact factor: 2.409

Review 5.  Quality of life measurement for patients with diseases of the airways.

Authors:  P W Jones
Journal:  Thorax       Date:  1991-09       Impact factor: 9.139

Review 6.  The potential of biotechnology to improve the quality of life of patients with renal failure.

Authors:  W E Bloembergen; A Laupacis
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

7.  Patients' self-reports of dyspnea: An important and independent outcome in chronic obstructive pulmonary disease.

Authors:  E G Eakin; R M Kaplan; A L Ries; D E Sassi-Dambron
Journal:  Ann Behav Med       Date:  1996-06

8.  Development and testing of a new measure of health status for clinical trials in heart failure.

Authors:  G H Guyatt; S Nogradi; S Halcrow; J Singer; M J Sullivan; E L Fallen
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

9.  Associations between symptoms, functioning, and perceptions of mastery with global self-rated health in patients with COPD: a cross-sectional study.

Authors:  Huong Q Nguyen; DorAnne Donesky-Cuenco; Virginia Carrieri-Kohlman
Journal:  Int J Nurs Stud       Date:  2007-11-05       Impact factor: 5.837

10.  Randomised controlled trial of weightlifting exercise in patients with chronic airflow limitation.

Authors:  K Simpson; K Killian; N McCartney; D G Stubbing; N L Jones
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.